Using a 3D culture model to study circulating tumor cells in head and neck cancer
Using A Three-dimentional Culture Model for Circulating Tumor Cells Combined With Molecular Bioassays in Patients With Head and Neck Cancer to Help Determine the Precise Choice of Systemic Drugs to Improve Survival Outcomes
Chang Gung Memorial Hospital · NCT06755762
This study is trying to see how circulating tumor cells from patients with head and neck cancer behave in a lab setting to better understand how the cancer spreads and comes back.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 88 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Chang Gung Memorial Hospital (other) |
| Drugs / interventions | pembrolizumab, nivolumab, cetuximab, chemotherapy |
| Locations | 1 site (Taoyuan) |
| Trial ID | NCT06755762 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate circulating tumor cells (CTCs) in patients with head and neck squamous cell carcinoma (HNSCC) using a 3D organoid culture model. The researchers will isolate high-purity CTCs from blood samples using a specialized device and analyze them to gain insights into cancer metastasis and potential biomarkers. The study focuses on understanding the molecular mechanisms behind cancer recurrence and progression, which remain poorly understood. By cultivating nearly 100% viable CTCs, the study seeks to enhance the utility of CTCs in cancer research.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with metastatic head and neck squamous cell carcinoma or healthy participants without cancer for comparison.
Not a fit: Patients with serious illnesses or those who do not meet the inclusion criteria may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and treatment strategies for patients with head and neck cancer.
How similar studies have performed: Other studies have shown promise in using circulating tumor cells for cancer research, but this specific approach with a 3D culture model is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. age ≥ 18 2. agree with blood drawing and follow the procedure of the trial a.health participants:without cancer over 5 yaers b.cancer participants:pathology: metastatic HNSCC patients Exclusion Criteria: 1. health participants:with serious illness 2. cancer participants:none
Where this trial is running
Taoyuan
- Chang Gung Memorial Hospital — Taoyuan, Taiwan (RECRUITING)
Study contacts
- Study coordinator: Chia-Hsun Hsieh, PhD
- Email: wisdom5000@gmail.com
- Phone: 0975366137
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Circulating Tumor Cell, HNSCC, circulating tumor cell, organoid